

Figure 5



Figure 5

Blood pressure-lowering effect by drug administration




Figure 7

Urinary protein inhibiting effect by drug administration




Figure 8

Thy-1 Nephritis model




Figure 9
Thy-1 Nephritis model





Figure 10 Thy-1 Nephritis model




20

Untreat

IM-2002

·Figure 11






Figure 12




Figure 13

Isonemia-reperfusion model





Figure 14








Figure 16
Stability of TM-2002 injectable lyophilized formulation




- 1. TM-2002 injectable lyophilized formulation-aqueous solution (1ml) diluted with saline (1.5 ml)  $\,$
- 2. TM-2002 hydrochloride (material; prepared when used for TLC)
- 3. TM·2002 hydrochloride (material) aqueous solution


Figure 17




ORP 150 immunostaining in WKY drug free group



ORP 150 immunostaining in SHR/NDmcr-cp drug free group





ORP 150 immunostaining in SHR drug free group



ORP 150 immunostaining in SHR/NDmcr—cp TM-2002 administered group







## This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record.

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

<b>8</b>
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.